Search

Your search keyword '"Bartlett, David L."' showing total 1,451 results
Start Over Author "Bartlett, David L."

Refine your results

more »

more »

more »

more »

more »
1,451 results on '"Bartlett, David L."'

107. Supplementary Figure 7 from Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment

Author

Theodoraki, Marie-Nicole, primary, Yerneni, Saigopalakrishna, primary, Sarkar, Saumendra N., primary, Orr, Brian, primary, Muthuswamy, Ravikumar, primary, Voyten, Jamie, primary, Modugno, Francesmary, primary, Jiang, Weijian, primary, Grimm, Melissa, primary, Basse, Per H., primary, Bartlett, David L., primary, Edwards, Robert P., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

108. Supplementary Figure 5 from Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment

Author

Theodoraki, Marie-Nicole, primary, Yerneni, Saigopalakrishna, primary, Sarkar, Saumendra N., primary, Orr, Brian, primary, Muthuswamy, Ravikumar, primary, Voyten, Jamie, primary, Modugno, Francesmary, primary, Jiang, Weijian, primary, Grimm, Melissa, primary, Basse, Per H., primary, Bartlett, David L., primary, Edwards, Robert P., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

109. Supplementary Figure 4 from Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment

Author

Theodoraki, Marie-Nicole, primary, Yerneni, Saigopalakrishna, primary, Sarkar, Saumendra N., primary, Orr, Brian, primary, Muthuswamy, Ravikumar, primary, Voyten, Jamie, primary, Modugno, Francesmary, primary, Jiang, Weijian, primary, Grimm, Melissa, primary, Basse, Per H., primary, Bartlett, David L., primary, Edwards, Robert P., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

110. Data from Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment

Author

Theodoraki, Marie-Nicole, primary, Yerneni, Saigopalakrishna, primary, Sarkar, Saumendra N., primary, Orr, Brian, primary, Muthuswamy, Ravikumar, primary, Voyten, Jamie, primary, Modugno, Francesmary, primary, Jiang, Weijian, primary, Grimm, Melissa, primary, Basse, Per H., primary, Bartlett, David L., primary, Edwards, Robert P., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

111. Supplementary Data from A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients

Author

Zeh, Herbert J., primary, Bahary, Nathan, primary, Boone, Brian A., primary, Singhi, Aatur D., primary, Miller-Ocuin, Jennifer Lee, primary, Normolle, Daniel P., primary, Zureikat, Amer H., primary, Hogg, Melissa E., primary, Bartlett, David L., primary, Lee, Kenneth K., primary, Tsung, Allan, primary, Marsh, J. Wallis, primary, Murthy, Pranav, primary, Tang, Daolin, primary, Seiser, Natalie, primary, Amaravadi, Ravi K., primary, Espina, Virginia, primary, Liotta, Lance, primary, and Lotze, Michael T., primary

Published
2023
Full Text
View/download PDF

112. Supplementary Figure 2 from Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment

Author

Theodoraki, Marie-Nicole, primary, Yerneni, Saigopalakrishna, primary, Sarkar, Saumendra N., primary, Orr, Brian, primary, Muthuswamy, Ravikumar, primary, Voyten, Jamie, primary, Modugno, Francesmary, primary, Jiang, Weijian, primary, Grimm, Melissa, primary, Basse, Per H., primary, Bartlett, David L., primary, Edwards, Robert P., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

113. Supplementary Figure 6 from Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment

Author

Theodoraki, Marie-Nicole, primary, Yerneni, Saigopalakrishna, primary, Sarkar, Saumendra N., primary, Orr, Brian, primary, Muthuswamy, Ravikumar, primary, Voyten, Jamie, primary, Modugno, Francesmary, primary, Jiang, Weijian, primary, Grimm, Melissa, primary, Basse, Per H., primary, Bartlett, David L., primary, Edwards, Robert P., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

114. Supplementary Figure 1 from Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment

Author

Theodoraki, Marie-Nicole, primary, Yerneni, Saigopalakrishna, primary, Sarkar, Saumendra N., primary, Orr, Brian, primary, Muthuswamy, Ravikumar, primary, Voyten, Jamie, primary, Modugno, Francesmary, primary, Jiang, Weijian, primary, Grimm, Melissa, primary, Basse, Per H., primary, Bartlett, David L., primary, Edwards, Robert P., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

115. Data from Neutrophil Extracellular Traps Drive Mitochondrial Homeostasis in Tumors to Augment Growth

Author

Yazdani, Hamza O., primary, Roy, Eva, primary, Comerci, Alexander J., primary, van der Windt, Dirk J., primary, Zhang, Hongji, primary, Huang, Hai, primary, Loughran, Patricia, primary, Shiva, Sruti, primary, Geller, David A., primary, Bartlett, David L., primary, Tsung, Allan, primary, Sheng, Tai, primary, Simmons, Richard L., primary, and Tohme, Samer, primary

Published
2023
Full Text
View/download PDF

116. Supplementary Data from Neutrophil Extracellular Traps Drive Mitochondrial Homeostasis in Tumors to Augment Growth

Author

Yazdani, Hamza O., primary, Roy, Eva, primary, Comerci, Alexander J., primary, van der Windt, Dirk J., primary, Zhang, Hongji, primary, Huang, Hai, primary, Loughran, Patricia, primary, Shiva, Sruti, primary, Geller, David A., primary, Bartlett, David L., primary, Tsung, Allan, primary, Sheng, Tai, primary, Simmons, Richard L., primary, and Tohme, Samer, primary

Published
2023
Full Text
View/download PDF

117. Supplementary Figure 3 from Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment

Author

Theodoraki, Marie-Nicole, primary, Yerneni, Saigopalakrishna, primary, Sarkar, Saumendra N., primary, Orr, Brian, primary, Muthuswamy, Ravikumar, primary, Voyten, Jamie, primary, Modugno, Francesmary, primary, Jiang, Weijian, primary, Grimm, Melissa, primary, Basse, Per H., primary, Bartlett, David L., primary, Edwards, Robert P., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

118. Supplementary Figure 3 from Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

Author

John, Liza B., primary, Howland, Linda J., primary, Flynn, Jacqueline K., primary, West, Alison C., primary, Devaud, Christel, primary, Duong, Connie P., primary, Stewart, Trina J., primary, Westwood, Jenny A., primary, Guo, Z. Sheng, primary, Bartlett, David L., primary, Smyth, Mark J., primary, Kershaw, Michael H., primary, and Darcy, Phillip K., primary

Published
2023
Full Text
View/download PDF

119. Supplementary Figure Legends 1-5 from Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

Author

John, Liza B., primary, Howland, Linda J., primary, Flynn, Jacqueline K., primary, West, Alison C., primary, Devaud, Christel, primary, Duong, Connie P., primary, Stewart, Trina J., primary, Westwood, Jenny A., primary, Guo, Z. Sheng, primary, Bartlett, David L., primary, Smyth, Mark J., primary, Kershaw, Michael H., primary, and Darcy, Phillip K., primary

Published
2023
Full Text
View/download PDF

120. Supplementary Figure 2 from NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

Author

Muthuswamy, Ravikumar, primary, Berk, Erik, primary, Junecko, Beth Fallert, primary, Zeh, Herbert J., primary, Zureikat, Amer H., primary, Normolle, Daniel, primary, Luong, The Minh, primary, Reinhart, Todd A., primary, Bartlett, David L., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

121. Supplementary Figure 4 from NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

Author

Muthuswamy, Ravikumar, primary, Berk, Erik, primary, Junecko, Beth Fallert, primary, Zeh, Herbert J., primary, Zureikat, Amer H., primary, Normolle, Daniel, primary, Luong, The Minh, primary, Reinhart, Todd A., primary, Bartlett, David L., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

122. Supplementary Figure 2 from Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

Author

John, Liza B., primary, Howland, Linda J., primary, Flynn, Jacqueline K., primary, West, Alison C., primary, Devaud, Christel, primary, Duong, Connie P., primary, Stewart, Trina J., primary, Westwood, Jenny A., primary, Guo, Z. Sheng, primary, Bartlett, David L., primary, Smyth, Mark J., primary, Kershaw, Michael H., primary, and Darcy, Phillip K., primary

Published
2023
Full Text
View/download PDF

123. Supplementary Figure 6 from NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

Author

Muthuswamy, Ravikumar, primary, Berk, Erik, primary, Junecko, Beth Fallert, primary, Zeh, Herbert J., primary, Zureikat, Amer H., primary, Normolle, Daniel, primary, Luong, The Minh, primary, Reinhart, Todd A., primary, Bartlett, David L., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

124. Supplementary Figure 4 from Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

Author

John, Liza B., primary, Howland, Linda J., primary, Flynn, Jacqueline K., primary, West, Alison C., primary, Devaud, Christel, primary, Duong, Connie P., primary, Stewart, Trina J., primary, Westwood, Jenny A., primary, Guo, Z. Sheng, primary, Bartlett, David L., primary, Smyth, Mark J., primary, Kershaw, Michael H., primary, and Darcy, Phillip K., primary

Published
2023
Full Text
View/download PDF

125. Data from Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

Author

John, Liza B., primary, Howland, Linda J., primary, Flynn, Jacqueline K., primary, West, Alison C., primary, Devaud, Christel, primary, Duong, Connie P., primary, Stewart, Trina J., primary, Westwood, Jenny A., primary, Guo, Z. Sheng, primary, Bartlett, David L., primary, Smyth, Mark J., primary, Kershaw, Michael H., primary, and Darcy, Phillip K., primary

Published
2023
Full Text
View/download PDF

127. Supplementary Figure 1 from Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

Author

John, Liza B., primary, Howland, Linda J., primary, Flynn, Jacqueline K., primary, West, Alison C., primary, Devaud, Christel, primary, Duong, Connie P., primary, Stewart, Trina J., primary, Westwood, Jenny A., primary, Guo, Z. Sheng, primary, Bartlett, David L., primary, Smyth, Mark J., primary, Kershaw, Michael H., primary, and Darcy, Phillip K., primary

Published
2023
Full Text
View/download PDF

128. Supplementary Figure 5 from Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

Author

John, Liza B., primary, Howland, Linda J., primary, Flynn, Jacqueline K., primary, West, Alison C., primary, Devaud, Christel, primary, Duong, Connie P., primary, Stewart, Trina J., primary, Westwood, Jenny A., primary, Guo, Z. Sheng, primary, Bartlett, David L., primary, Smyth, Mark J., primary, Kershaw, Michael H., primary, and Darcy, Phillip K., primary

Published
2023
Full Text
View/download PDF

129. Supplementary Figure 1 from NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

Author

Muthuswamy, Ravikumar, primary, Berk, Erik, primary, Junecko, Beth Fallert, primary, Zeh, Herbert J., primary, Zureikat, Amer H., primary, Normolle, Daniel, primary, Luong, The Minh, primary, Reinhart, Todd A., primary, Bartlett, David L., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

130. Supplementary Figure Legends 1-6 from NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

Author

Muthuswamy, Ravikumar, primary, Berk, Erik, primary, Junecko, Beth Fallert, primary, Zeh, Herbert J., primary, Zureikat, Amer H., primary, Normolle, Daniel, primary, Luong, The Minh, primary, Reinhart, Todd A., primary, Bartlett, David L., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

131. Supplementary Figure 5 from NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

Author

Muthuswamy, Ravikumar, primary, Berk, Erik, primary, Junecko, Beth Fallert, primary, Zeh, Herbert J., primary, Zureikat, Amer H., primary, Normolle, Daniel, primary, Luong, The Minh, primary, Reinhart, Todd A., primary, Bartlett, David L., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

132. Supplementary Figure 3 from NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

Author

Muthuswamy, Ravikumar, primary, Berk, Erik, primary, Junecko, Beth Fallert, primary, Zeh, Herbert J., primary, Zureikat, Amer H., primary, Normolle, Daniel, primary, Luong, The Minh, primary, Reinhart, Todd A., primary, Bartlett, David L., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

133. Data from NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells

Author

Muthuswamy, Ravikumar, primary, Berk, Erik, primary, Junecko, Beth Fallert, primary, Zeh, Herbert J., primary, Zureikat, Amer H., primary, Normolle, Daniel, primary, Luong, The Minh, primary, Reinhart, Todd A., primary, Bartlett, David L., primary, and Kalinski, Pawel, primary

Published
2023
Full Text
View/download PDF

136. A Real-Time Mobile Intervention to Reduce Sedentary Behavior Before and After Cancer Surgery: Pilot Randomized Controlled Trial

Author

Low, Carissa A, primary, Danko, Michaela, additional, Durica, Krina C, additional, Vega, Julio, additional, Li, Meng, additional, Kunta, Abhineeth Reddy, additional, Mulukutla, Raghu, additional, Ren, Yiyi, additional, Sereika, Susan M, additional, Bartlett, David L, additional, Bovbjerg, Dana H, additional, Dey, Anind K, additional, and Jakicic, John M, additional

Published
2023
Full Text
View/download PDF

146. Predicting Severe Complications from Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: A Data-Driven, Machine Learning Approach to Augment Clinical Judgment.

Author

Adam, Mohamed A., Zhou, Helen, Byrd, Jonathan, Greenberg, Anya L., Kelly, Yvonne M., Hall, Lauren, Jones, Heather L., Pingpank, James F., Lipton, Zachary C., Bartlett, David L., and Choudry, Haroon M.

Abstract

Background: CRS-HIPEC provides oncologic benefit in well-selected patients with peritoneal carcinomatosis; however, it is a morbid procedure. Decision tools for preoperative patient selection are limited. We developed a risk score to predict severity of 90 day complications for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Patients and Methods: Adults who underwent CRS-HIPEC at the University of Pittsburgh Medical Center (March 2001–April 2020) were analyzed as part of this study. Primary endpoint was severe complications within 90 days following CRS-HIPEC, defined using Comprehensive Complication Index (CCI) scores as a dichotomous (determined using restricted cubic splines) and continuous variable. Data were divided into training and test sets. Several machine learning and traditional algorithms were considered. Results: For the 1959 CRS-HIPEC procedures included, CCI ranged from 0 to 100 (median 32.0). Adjusted restricted cubic splines model defined severe complications as CCI > 61. A minimum of 20 variables achieved optimal performance of any of the models. Linear regression achieved the highest area under the receiving operator characteristic curve (AUC, 0.74) and outperformed the NSQIP Surgical Risk calculator (AUC 0.80 vs. 0.66). Factors most positively associated with severe complications included peritoneal carcinomatosis index score, symptomatic status, and undergoing pancreatectomy, while American Society of Anesthesiologists 2 class, appendiceal diagnosis, and preoperative albumin were most negatively associated with severe complications. Conclusions: This study refines our ability to predict severe complications within 90 days of discharge from a hospitalization in which CRS-HIPEC was performed. This advancement is timely and relevant given the growing interest in this procedure and may have implications for patient selection, patient and referring provider comfort, and survival. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

147. Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases.

Author

Hamed, Ahmed B., Shuai, Yongli, Derby, Joshua, Holtzman, Matthew P., Ongchin, Melanie, Bartlett, David L., Pingpank, James F., Pai, Reetesh, Singhi, Aatur, and Choudry, Haroon A.

Abstract

Background: Colorectal cancer leads to peritoneal metastases (CRPM) in 10% of cases. Cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS-HIPEC) improves survival. Primary tumor location and abnormalities in RAS, BRAF, and mismatch repair/microsatellite stability (MMR/MSI) may affect post-CRS-HIPEC survival, but studies have not been consistent. We estimated the effects of primary tumor site and genomic alterations on post-CRS-HIPEC survival. Methods: This retrospective cohort study included CRS-HIPEC cases for CRPM at a high-volume center from 2001 to 2020. Next-generation sequencing and microsatellite testing defined the RAS, BRAF, and MMR/MSI genotypes. Adjusted effects of tumor sidedness and genomics on survival were evaluated using a multivariable Cox proportional hazards model. We analyzed these variables' effects on progression-free survival and the effects of immune checkpoint-inhibitors. Results: A total of 250 patients underwent CRS-HIPEC with testing for RAS, BRAF, and MMR/MSI; 50.8% of patients were RAS-mutated, 12.4% were BRAF-mutated, and 6.8% were deficient-MMR/MSI-high (dMMR/MSI-H). Genomic alterations predominated in right-sided cancers. After adjustment for comorbidities and oncological and perioperative variables, rectal origin [hazard ratio (HR) 1.9, p = 0.01], RAS mutation (HR 1.6, p = 0.01), and BRAF mutation (HR 1.7, p = 0.05) were associated with worse survival. RAS mutation was also associated with shorter progression-free survival (HR 1.6, p = 0.01 at 6 months post-operatively), and dMMR/MSI-H status was associated with superior survival (HR 0.3, p = 0.01 at 2 years). dMMR/MSI-H patients receiving immune checkpoint-inhibitors trended toward superior survival. Conclusions: Rectal origin, RAS mutations, and BRAF mutations are each associated with poorer survival after CRS-HIPEC for CRPM. Patients with CRPM and dMMR/MSI-H status have superior survival. Further research should evaluate benefits of immune checkpoint-inhibitors in this subgroup. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results